Alio Karamba
YOU?
Author Swipe
View article: Spillover of Azithromycin Mass Drug Administration and Child Survival
Spillover of Azithromycin Mass Drug Administration and Child Survival Open
Importance World Health Organization guidelines on azithromycin mass drug administration for child survival target infants aged 1 to 11 months, although prior studies included those aged 1 to 59 months. The AVENIR trial suggested that infa…
View article: Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1–11 Versus 1–59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in Niger
Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1–11 Versus 1–59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in Niger Open
Azithromycin mass drug administration (MDA) for 1- to 59-month-olds reduces child mortality. However, guidelines restrict eligibility to 1- to 11-month-olds because of concerns about antimicrobial resistance. This cluster-randomized implem…
View article: Distance to Health Centers and Effectiveness of Azithromycin Mass Administration for Children in Niger
Distance to Health Centers and Effectiveness of Azithromycin Mass Administration for Children in Niger Open
Importance The MORDOR (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) trial demonstrated that mass azithromycin administration reduced mortality by 18% among children aged 1 to 59 months in Niger. The identificatio…